Gilead’s rosy guidance sends shares upwards

12 February 2025

US biotech major Gilead Sciences (Nasdaq: GILD) was trading nearly 5% higher in Wednesday’s pre-market trading after presenting its fourth quarter and 2024 financial results, and guidance for the year ahead.

The latter likely led to the share price rise, with Gilead’s guidance for earnings well ahead of what analysts were expecting.

For 2025, the Californian company said it expects adjusted earnings of $7.70 to $8.10 per share, on product sales of $28.2 billion to $28.6 billion. Even the low end of the earnings range is above analysts' projections of $7.58 per share, according to LSEG data. They are predicting annual revenue of $28.42 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK